Delighted to welcome Dipal Doshi to our Board and looking forward to working with him as we write the next chapter of ashibio!
We are incredibly excited to welcome Dipal Doshi, CEO of Entrada Therapeutics, to our Board of Directors. Dipal has a long record of accomplishment setting strategy and driving operational and commercial growth for #biopharma companies, and his experience will be invaluable in the next phase of āshibio. We look forward to his involvement as we develop novel therapies for bone and connective tissue disorders, including our lead asset for potential treatment of fibrodysplasia ossificans progressiva (FOP). Read the announcement here: https://bit.ly/3XrQOY8 #raredisease #biotech #lifesciences